诺奖得主马歇尔:幽门螺杆菌患者不必分餐,警惕抗生素耐药性

2017-06-13 陈明明 澎湃新闻

他是2005年诺贝尔生理学或医学奖得主;他提出了“幽门螺杆菌是大多数胃溃疡和胃炎的成因”这一学说;他为了验证其学说的科学性曾在1982年亲自喝下了试管里的幽门螺杆菌,不惜患上胃溃疡而后使用抗生素治愈。他,是“幽门螺杆菌之父”巴里·马歇尔教授。如今,上海市民在家门口就能让这位来自澳大利亚的专家为自己看诊。6月13日上午8时许,位于浦东即墨路的同济大学附属上海东方医院本部三楼特需门诊门口人头攒动,

他是2005年诺贝尔生理学或医学奖得主;他提出了“幽门螺杆菌是大多数胃溃疡和胃炎的成因”这一学说;他为了验证其学说的科学性曾在1982年亲自喝下了试管里的幽门螺杆菌,不惜患上胃溃疡而后使用抗生素治愈。

他,是“幽门螺杆菌之父”巴里·马歇尔教授。如今,上海市民在家门口就能让这位来自澳大利亚的专家为自己看诊。

6月13日上午8时许,位于浦东即墨路的同济大学附属上海东方医院本部三楼特需门诊门口人头攒动,通过特需门诊预约筛选的多位患者一大早就来等候巴里·马歇尔教授。为了提高门诊效率,此次义诊患者均为复诊,并被通知带好胃镜报告和碳13呼气报告。

2005年,马歇尔教授与病理学家沃伦教授共同获得诺贝尔生理学或医学奖,彼时的马歇尔才54岁。更加难能可贵的是,马歇尔从未因获得诺奖而放弃临床工作,他挤出一切可能时间坚持门诊亲自看病人,被评为“全球最受欢迎的诺贝尔奖获得者”。

世卫组织已经明确,幽门螺杆菌是导致胃溃疡、胃炎和胃癌的第一致病因子。流行病学调查显示,目前中国超过50%的人感染幽门螺杆菌,预计有7亿感染者,然而目前临床诊疗的根除率却不容乐观。

对于幽门螺杆菌,国内医生主要依据“中国幽门螺杆菌感染诊治共识”和临床诊疗经验来开展治疗,常规一般采用含有铋剂的四联方案连续使用二周,对于不同患者的治疗方案基本一致。由于抗生素的滥用,幽门螺杆菌耐药性不断增强,传统治疗方法的有效性也在不断受到质疑。

那么,预防幽门螺杆菌需不需要分餐?无症状患者服用抗生素根除幽门螺杆菌是否属于过度治疗?如何应对抗生素耐药性?为此,马歇尔团队接受了记者专访。

感染者无需分餐,接吻可传染

澎湃新闻:幽门螺杆菌会通过“口口传播”,被感染的患者在家就餐是否要采取分餐制?情侣之间接吻是不是也会被传染?

马歇尔团队:“口-口”和“粪-口”是幽门螺杆菌的主要传播途径,以“口-口传播”为主。前者主要通过唾液在母亲至儿童和夫妻之间传播,后者主要通过感染者粪便污染水源传播。儿童和成人均为易感人群。

感染性疾病分为传染性和非传染性,因此幽门螺杆菌胃炎定义为传染病更为确切(infectious disease既可译为“感染性疾病”,也可译为“传染病”)。2015年国际指南达成的京都共识,第一次确认了幽门螺杆菌是强致病菌,去年中国医学会才承认这个共识。但是幽门螺杆菌感染者无需像甲肝、乙肝携带者一样和家人分餐。

要从幽门螺杆菌本身特异性来看待这个问题,幽门螺杆菌一方面不好治,但又存在于很多人的胃部。幽门螺杆菌和免疫系统关系很微妙,幽门螺杆菌和人类共存了几万年。幽门螺杆菌是厌氧菌,到目前为止,是唯一能在人体胃部强酸环境下存活的细菌。如果暴露在空气自然条件下,很难长期存活,所以通过餐具被感染的几率很低,个人认为热食物中是没有这个问题的,分餐的必要性不大。日常生活中,幽门螺杆菌具体如何传播没有明确说法,目前尚无科学证实分餐能降低幽门螺杆菌的感染,所以无须过度恐慌而过多地改变生活习惯。

幽门螺杆菌的英文名为Helicobacter Pylori(简称HP),就是因为和直升飞机螺旋桨(helicopter)相似,幽门螺杆菌的鞭毛在尾部,像螺旋桨一样,是会游动的细菌,如果有液体存在,是会游动的。幽门螺杆菌会从胃部“游”到口腔,所以会“口口传播”,而情侣之间接吻是有被传染的可能的。

记者:不少幽门螺杆菌患者在幼年时期就被感染了,原因何在?是和抵抗力有关吗?

马歇尔团队:一般妈妈有幽门螺杆菌,宝宝也可能被感染,患者年幼时就被感染到幽门螺杆菌的原因大部分是因为其父母感染了幽门螺杆菌,再将嘴里咀嚼过的食物喂给孩子引起的传染,所以父母不该给孩子哺食。

人体抵抗力好坏对于是否感染幽门螺杆菌影响并不大,关键在于是否被暴露在感染源,这和环境有关,比如在有些发达国家,随着周围环境条件的改善,幽门螺杆菌感染率比较低,当地小孩子无论抵抗力高低,血液检测的抗原含量都不高。但在中国,尤其是在江苏一带,幽门螺杆菌的感染率高达70%,当地出生的孩子就很容易暴露在感染源中。

传统疗法为何根治失败

记者:流行病学调查显示,中国已有超过50%的人感染幽门螺杆菌,临床根除率低于65%。如果被根除,复发概率高不高?

马歇尔团队:中国幽门螺杆菌感染者众多,但治疗方案却是“通常方案”,无论是谁被检查出来感染幽门螺杆菌,都是使用同一种治疗方案,无法体现个体化的区别性。

但事实上,幽门螺杆菌不同于其他细菌,它在每个个体的胃部区别性很大,尤其是对药物敏感性区别性颇大。给药情况一样的话,药物敏感度不够高,细菌容易产生耐药性,更糟的情况是适得其反,增加疾病严重状况,国内遇到这个情况,很多医生索性建议不要治了。所以会给人一种“幽门螺杆菌不容易治疗”的错觉,其实是因为没有个性化精准治疗导致的。

我们团队经过很长时间研究不同个体所携带的不同菌种、不同地区容易流行的各种病株对抗生素的耐药性,比如,在中国四川地区,幽门螺杆菌感染者对甲硝锉的耐药性特别高,所以当地患者如果选择甲硝锉作为抗生素备选方案,治疗效果就不好,会导致细菌产生更大的耐药性。我们会以家庭为单位,通常来自同一个家庭患者的幽门螺杆菌是同一个菌种,我们会通过一系列分析得出一个最优方案,个性化精准治疗的治愈率超过95%。

此次签约同济大学附属上海东方医院不是只给患者看门诊这么简单,我们团队核心技术是在对患者进行药敏试验、基因测序、生物标志物分析鉴定的基础上,更准确分析患者所感染的幽门螺杆菌对何种抗生素最为敏感,通过精确寻求病因,对疾病不同状态及过程进行分类,选择不同的治疗靶点和诊疗措施,从而为患者提供个性化的精准治疗,进一步提高根治率,同时减少滥用抗生素的可能性。

幽门螺杆菌真正根治了一般不会复发,连第二次被传染都很少,所谓的复发就是没有真正根除,因为有些药只是抑制了幽门螺杆菌,但没有真正杀除,再次感染的原因是因为第一次就没彻底根除。

记者:为何有些幽门螺杆菌感染患者在服用三联或四联抗生素后,症状反而加重?如果第一次服用抗生素没根除,之后继续服用抗生素会不会有副作用?

马歇尔团队:比其他细菌,幽门螺杆菌的治疗需要考虑得更细致深入。幽门螺杆菌确实和人类共同生存的历史悠久,但同时也和人类共同进化,所以就导致了幽门螺杆菌是唯一能在强酸胃部环境下生存的细菌。幽门螺杆菌有不同的菌种,比如有些是欧洲流行的,有些是亚洲流行的,有些幽门螺杆菌有细胞外毒素,有些则没有。如果患者携带的幽门螺杆菌是耐药菌种,采用中国国内普遍方案处理的话,那么就治疗无效,如果之后还使用第一次治疗时的抗生素会适得其反。

国内很多医生对于根除幽门螺杆菌的方案千篇一律,无针对性,只是根据国家医学会幽门螺杆菌治疗指南来执行。但实际上,在幽门螺杆菌治疗上,指南并不是个性化治疗,有些患者就无法根除。给患者用了很多次同类抗生素,全部耐药后就会产生白色真菌,导致症状更严重。

第一次根除失败后,很容易导致患者携带的幽门螺杆菌产生耐药性,所以之后不建议再次反复使用之前的抗生素。

感染者无症状也要治疗

记者:为何有些患者验血验出来幽门螺杆菌抗体阳性,但是碳13/14呼气测试检查出来却是阴性?

马歇尔团队:验血验出来幽门螺杆菌抗体阳性,但碳13/14呼气测试查出来是阴性,这种情况表示该患者曾经感染过幽门螺杆菌,可能后来自愈了。有些感染了幽门螺杆菌的患者是能够自愈的。人体有自愈成功存在,但因为长期暴露在这个环境中,所以人自愈后又会被感染。采用中国目前流行的方案,弊端比较多,造成普通民众恐慌,觉得这个细菌很难杀。国际共识是,任何胃部不适患者,首先就是要根除幽门螺杆菌,80%的原因在这第一步根除的时候就解决了。

记者:无任何胃部不适症状的幽门螺杆菌感染者,究竟需不需要接受治疗?

马歇尔团队:有些民众甚至医生会认为幽门螺杆菌没引起特别明显的症状就不用治疗,有些国内专家甚至认为幽门螺杆菌和人体共生存在有益作用,但国际上的共识是幽门螺杆菌是强致病菌,对于这个问题,可以给出肯定答案——幽门螺杆菌无任何益处。

所谓的无症状幽门螺杆菌感染,其实只是患者自己没感觉到,如果放大了看,在胃壁上仍有小的胃溃疡存在,没感觉到不代表没发生。所以,无任何胃部不适症状的幽门螺杆菌感染者接受治疗,不属于过度治疗。即使患者没有症状,也不论有无消化性溃疡、胃癌等并发症,幽门螺杆菌胃炎应被定义为一种感染性疾病

如今日本幽门螺杆菌感染率很低,但是在上个世纪,日本幽门螺杆菌患者很高,和地区发达水平卫生情况有一定关系,但仍需进一步验证。当时有个误解,人人都有幽门螺杆菌,是环境中常见的病菌,是不是就不用治了,但这个观点错误,治不治的前后感觉,患者本人在根除后胃部不适后,症状有很大缓解,这是有明显区别的。

建议健康人每年做筛查

记者:没有感染幽门螺杆菌的人也需要每年做筛查吗?

马歇尔团队:感染了幽门螺杆菌并不是说就一定会得胃癌,但是建议,即便是健康人也有必要每年做幽门螺杆菌筛查,因为每个人都有机会暴露在(易感染环境中),尤其在中国感染率高。

幽门螺杆会菌刺激胃壁,产生胃溃疡,而胃溃疡有一定几率导致胃癌,消除幽门螺杆菌能规避胃癌风险。胃癌发生和幽门螺杆菌的菌种、胃酸分泌高低、饮食习惯有关。通常胃酸分泌高不容易导致胃癌 。

记者:民间流传着某些中药、新西兰麦卡卢蜂蜜、丁香茶等可以杀除幽门螺杆菌的说法,靠不靠谱?

马歇尔团队:有些中药确实有一定疗效,但还有待进一步验证,至于蜂蜜、茶等自然疗法、替代性的辅助疗法的科学性还有待进一步探索,目前无相关研究能给出明确答案。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (20)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1811713, encodeId=8e981811e13fb, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Jan 04 00:33:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215699, encodeId=4dd02156995e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39bc2081502, createdName=基因傀儡, createdTime=Mon Jun 26 21:12:26 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604452, encodeId=7d1a160445275, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462316, encodeId=7e661462316a8, content=<a href='/topic/show?id=5c0c9191e10' target=_blank style='color:#2F92EE;'>#诺奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91917, encryptionId=5c0c9191e10, topicName=诺奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4d36483905, createdName=wumeihua90, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441638, encodeId=cd2a14416388c, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211011, encodeId=7a8521101112, content=好文章,值得拜读,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Jun 15 08:12:20 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210865, encodeId=69d4210865e2, content=学习了。。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Thu Jun 15 06:05:11 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210695, encodeId=315d2106955e, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:46:19 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210663, encodeId=10422106631b, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Jun 14 13:33:34 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210622, encodeId=db20210622dc, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Wed Jun 14 11:13:47 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2018-01-04 kcb069
  2. [GetPortalCommentsPageByObjectIdResponse(id=1811713, encodeId=8e981811e13fb, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Jan 04 00:33:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215699, encodeId=4dd02156995e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39bc2081502, createdName=基因傀儡, createdTime=Mon Jun 26 21:12:26 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604452, encodeId=7d1a160445275, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462316, encodeId=7e661462316a8, content=<a href='/topic/show?id=5c0c9191e10' target=_blank style='color:#2F92EE;'>#诺奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91917, encryptionId=5c0c9191e10, topicName=诺奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4d36483905, createdName=wumeihua90, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441638, encodeId=cd2a14416388c, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211011, encodeId=7a8521101112, content=好文章,值得拜读,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Jun 15 08:12:20 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210865, encodeId=69d4210865e2, content=学习了。。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Thu Jun 15 06:05:11 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210695, encodeId=315d2106955e, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:46:19 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210663, encodeId=10422106631b, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Jun 14 13:33:34 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210622, encodeId=db20210622dc, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Wed Jun 14 11:13:47 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2017-06-26 基因傀儡

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1811713, encodeId=8e981811e13fb, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Jan 04 00:33:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215699, encodeId=4dd02156995e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39bc2081502, createdName=基因傀儡, createdTime=Mon Jun 26 21:12:26 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604452, encodeId=7d1a160445275, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462316, encodeId=7e661462316a8, content=<a href='/topic/show?id=5c0c9191e10' target=_blank style='color:#2F92EE;'>#诺奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91917, encryptionId=5c0c9191e10, topicName=诺奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4d36483905, createdName=wumeihua90, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441638, encodeId=cd2a14416388c, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211011, encodeId=7a8521101112, content=好文章,值得拜读,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Jun 15 08:12:20 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210865, encodeId=69d4210865e2, content=学习了。。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Thu Jun 15 06:05:11 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210695, encodeId=315d2106955e, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:46:19 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210663, encodeId=10422106631b, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Jun 14 13:33:34 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210622, encodeId=db20210622dc, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Wed Jun 14 11:13:47 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1811713, encodeId=8e981811e13fb, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Jan 04 00:33:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215699, encodeId=4dd02156995e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39bc2081502, createdName=基因傀儡, createdTime=Mon Jun 26 21:12:26 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604452, encodeId=7d1a160445275, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462316, encodeId=7e661462316a8, content=<a href='/topic/show?id=5c0c9191e10' target=_blank style='color:#2F92EE;'>#诺奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91917, encryptionId=5c0c9191e10, topicName=诺奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4d36483905, createdName=wumeihua90, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441638, encodeId=cd2a14416388c, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211011, encodeId=7a8521101112, content=好文章,值得拜读,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Jun 15 08:12:20 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210865, encodeId=69d4210865e2, content=学习了。。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Thu Jun 15 06:05:11 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210695, encodeId=315d2106955e, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:46:19 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210663, encodeId=10422106631b, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Jun 14 13:33:34 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210622, encodeId=db20210622dc, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Wed Jun 14 11:13:47 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2017-06-15 wumeihua90
  5. [GetPortalCommentsPageByObjectIdResponse(id=1811713, encodeId=8e981811e13fb, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Jan 04 00:33:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215699, encodeId=4dd02156995e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39bc2081502, createdName=基因傀儡, createdTime=Mon Jun 26 21:12:26 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604452, encodeId=7d1a160445275, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462316, encodeId=7e661462316a8, content=<a href='/topic/show?id=5c0c9191e10' target=_blank style='color:#2F92EE;'>#诺奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91917, encryptionId=5c0c9191e10, topicName=诺奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4d36483905, createdName=wumeihua90, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441638, encodeId=cd2a14416388c, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211011, encodeId=7a8521101112, content=好文章,值得拜读,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Jun 15 08:12:20 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210865, encodeId=69d4210865e2, content=学习了。。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Thu Jun 15 06:05:11 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210695, encodeId=315d2106955e, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:46:19 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210663, encodeId=10422106631b, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Jun 14 13:33:34 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210622, encodeId=db20210622dc, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Wed Jun 14 11:13:47 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1811713, encodeId=8e981811e13fb, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Jan 04 00:33:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215699, encodeId=4dd02156995e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39bc2081502, createdName=基因傀儡, createdTime=Mon Jun 26 21:12:26 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604452, encodeId=7d1a160445275, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462316, encodeId=7e661462316a8, content=<a href='/topic/show?id=5c0c9191e10' target=_blank style='color:#2F92EE;'>#诺奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91917, encryptionId=5c0c9191e10, topicName=诺奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4d36483905, createdName=wumeihua90, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441638, encodeId=cd2a14416388c, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211011, encodeId=7a8521101112, content=好文章,值得拜读,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Jun 15 08:12:20 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210865, encodeId=69d4210865e2, content=学习了。。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Thu Jun 15 06:05:11 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210695, encodeId=315d2106955e, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:46:19 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210663, encodeId=10422106631b, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Jun 14 13:33:34 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210622, encodeId=db20210622dc, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Wed Jun 14 11:13:47 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2017-06-15 1e10c84am36(暂无匿称)

    好文章,值得拜读,受益

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1811713, encodeId=8e981811e13fb, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Jan 04 00:33:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215699, encodeId=4dd02156995e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39bc2081502, createdName=基因傀儡, createdTime=Mon Jun 26 21:12:26 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604452, encodeId=7d1a160445275, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462316, encodeId=7e661462316a8, content=<a href='/topic/show?id=5c0c9191e10' target=_blank style='color:#2F92EE;'>#诺奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91917, encryptionId=5c0c9191e10, topicName=诺奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4d36483905, createdName=wumeihua90, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441638, encodeId=cd2a14416388c, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211011, encodeId=7a8521101112, content=好文章,值得拜读,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Jun 15 08:12:20 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210865, encodeId=69d4210865e2, content=学习了。。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Thu Jun 15 06:05:11 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210695, encodeId=315d2106955e, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:46:19 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210663, encodeId=10422106631b, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Jun 14 13:33:34 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210622, encodeId=db20210622dc, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Wed Jun 14 11:13:47 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2017-06-15 135****7952平儿

    学习了。。。。。。。。。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1811713, encodeId=8e981811e13fb, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Jan 04 00:33:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215699, encodeId=4dd02156995e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39bc2081502, createdName=基因傀儡, createdTime=Mon Jun 26 21:12:26 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604452, encodeId=7d1a160445275, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462316, encodeId=7e661462316a8, content=<a href='/topic/show?id=5c0c9191e10' target=_blank style='color:#2F92EE;'>#诺奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91917, encryptionId=5c0c9191e10, topicName=诺奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4d36483905, createdName=wumeihua90, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441638, encodeId=cd2a14416388c, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211011, encodeId=7a8521101112, content=好文章,值得拜读,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Jun 15 08:12:20 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210865, encodeId=69d4210865e2, content=学习了。。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Thu Jun 15 06:05:11 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210695, encodeId=315d2106955e, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:46:19 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210663, encodeId=10422106631b, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Jun 14 13:33:34 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210622, encodeId=db20210622dc, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Wed Jun 14 11:13:47 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2017-06-14 Y—xianghai

    学习了新知识

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1811713, encodeId=8e981811e13fb, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Jan 04 00:33:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215699, encodeId=4dd02156995e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39bc2081502, createdName=基因傀儡, createdTime=Mon Jun 26 21:12:26 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604452, encodeId=7d1a160445275, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462316, encodeId=7e661462316a8, content=<a href='/topic/show?id=5c0c9191e10' target=_blank style='color:#2F92EE;'>#诺奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91917, encryptionId=5c0c9191e10, topicName=诺奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4d36483905, createdName=wumeihua90, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441638, encodeId=cd2a14416388c, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211011, encodeId=7a8521101112, content=好文章,值得拜读,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Jun 15 08:12:20 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210865, encodeId=69d4210865e2, content=学习了。。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Thu Jun 15 06:05:11 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210695, encodeId=315d2106955e, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:46:19 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210663, encodeId=10422106631b, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Jun 14 13:33:34 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210622, encodeId=db20210622dc, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Wed Jun 14 11:13:47 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2017-06-14 李东泽

    很好,不错,以后会多学习

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1811713, encodeId=8e981811e13fb, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Thu Jan 04 00:33:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215699, encodeId=4dd02156995e, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39bc2081502, createdName=基因傀儡, createdTime=Mon Jun 26 21:12:26 CST 2017, time=2017-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604452, encodeId=7d1a160445275, content=<a href='/topic/show?id=13235544294' target=_blank style='color:#2F92EE;'>#抗生素耐药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55442, encryptionId=13235544294, topicName=抗生素耐药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69fc19187130, createdName=liuyg0234, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462316, encodeId=7e661462316a8, content=<a href='/topic/show?id=5c0c9191e10' target=_blank style='color:#2F92EE;'>#诺奖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91917, encryptionId=5c0c9191e10, topicName=诺奖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4d36483905, createdName=wumeihua90, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441638, encodeId=cd2a14416388c, content=<a href='/topic/show?id=64655544106' target=_blank style='color:#2F92EE;'>#抗生素耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55441, encryptionId=64655544106, topicName=抗生素耐药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cac4876897, createdName=12498bf3m26暂无昵称, createdTime=Thu Jun 15 14:33:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211011, encodeId=7a8521101112, content=好文章,值得拜读,受益, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Jun 15 08:12:20 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210865, encodeId=69d4210865e2, content=学习了。。。。。。。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Neru1qt53a14aACuSzg3TZhkTcsPYVibyHibhTZ5L4k9qIBWiaej4lgomIsGptf8N16E4mTuIq2DVdJXjPjmwZKrLib/0, createdBy=5a0f2055853, createdName=135****7952平儿, createdTime=Thu Jun 15 06:05:11 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210695, encodeId=315d2106955e, content=学习了新知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201006/4db877c2887649beb09cb5effd0b38c7/916f66edd48a4e77b20ebc3e14b6e45c.jpg, createdBy=141e1980133, createdName=Y—xianghai, createdTime=Wed Jun 14 15:46:19 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210663, encodeId=10422106631b, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Jun 14 13:33:34 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=210622, encodeId=db20210622dc, content=谢谢分享受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM5vZbLiaw0G6FFQ3J4obXJNXbFJZBOJIsBiasEmSFCxzhibZ2TT0xftAW5kV1SLyo6jg0hOMaJg1Alm15kbuoDUFIsUM4JP7bdvcA/0, createdBy=10082062447, createdName=医无止境。, createdTime=Wed Jun 14 11:13:47 CST 2017, time=2017-06-14, status=1, ipAttribution=)]
    2017-06-14 医无止境。

    谢谢分享受益匪浅

    0

相关资讯

他山之石,可以攻玉--借鉴国际共识,探讨我国Hp根除方案

自2012年第四次全国幽门螺杆菌感染处理共识会议以来,国际上发表了3个重要的幽门螺杆菌(Hp)感染处理共识报告,这些共识报告分别是:《幽门螺杆菌胃炎京都全球共识》、《多伦多成人幽门螺杆菌感染治疗共识》和最近已在互联网上预发表的《幽门螺杆菌感染的处理:Maastricht V/Florence共识》。第一个共识强调了Hp胃炎是一种传染性疾病,Hp胃炎相关消化不良是一种器质性疾病,根除Hp可作为胃

PLoS Pathog:重新定义幽门螺杆菌脂多糖O-抗原和核心寡糖结构域

细菌病原体幽门螺杆菌能够长期感染人类胃部并引起溃疡和胃癌。幽门螺杆菌脂多糖可以通过免疫逃避促进持续感染。尽管确认了幽门螺杆菌脂多糖在发病机制中的关键作用。但是其精确的结构域组织结构仍然未知。

幽门螺杆菌的自白:六招就能躲开我

大家好,我是幽门螺杆菌,由澳大利亚学者Marshall和Warren首次从人的胃黏膜中找到我后,近年来,我的名气越来越大,我平时喜欢待在人们的胃部和十二指肠各区域内,自然界中人是我唯一的传染源,一般通过粪-口传播。如果你不幸患了活动性胃炎、消化性溃疡、胃癌等病,说不定罪魁祸首就是我哦!我的厉害之处在于在全球自然人群的感染率超过50%,全世界没有哪一种慢性传染病会使全球超过半数的人口受到感染。我是一

PNAS:科学家成功解析诱发胃癌细菌的关键酶类结构

近日,一项刊登在国际杂志PNAS上的研究报告中,来自能源部橡树岭国家实验室的研究人员通过研究成功对诱发胃癌的细菌的关键酶类进行了解析;研究者指出,阐明酶类的结构以及幽门螺杆菌的代谢和生物学途径对于后期开发治疗幽门螺杆菌感染的新型药物提供了新的线索。

幽门螺杆菌阳性患者介入术后三联根除治疗可减少消化道出血

新疆医科大学第一附属医院学者在我刊发文称,对于经皮冠状动脉介入术(PCI)后的患者,幽门螺杆菌(Hp)感染可增加抗血小板药物治疗的上消化道出血风险,如采取Hp根除治疗可显着降低出血风险。

Gut:表皮生长因子受体抑制剂对幽门螺杆菌诱导上皮细胞炎症、DNA损伤及胃癌的预防

抑制表皮生长因子受体是一个预防幽门螺杆菌感染导致胃癌的潜在战略